Literature DB >> 12215243

The role of nitric oxide in cigarette smoking and nicotine addiction.

Wim Vleeming1, Bisoen Rambali, Antoon Opperhuizen.   

Abstract

The purpose of this study is to describe the interrelationship between nitric oxide (NO) and nicotine in cigarette smoking addiction, in view of the underlying hypothesis that NO contributes to smoking (nicotine) addiction, and to suggest the ways to improve prevention as well as cessation strategies. A literature search of Medline using the keywords nicotine and nitric oxide covering 1995 to May 2001 was made. Further information not obtained from the Medline search was derived from the references cited in these publications. Smokers are exposed first to high concentrations of inhaled NO from smoke and, second, to endogenously released NO after uptake of nicotine into the brain. As a result, the basal endogenous NO synthesis in airways and blood vessels of smokers is reduced. Subsequently, because NO is involved in maintaining airway dilatation, smokers may have constricted airways. During smoking, however, NO from smoke may dilate the constricted airways, allowing the smoke an easier passage into the lungs, and exposing the body and the brain to more nicotine. NO can endogenously be released by nicotine from nervous tissue, and may decrease the sympathetic output of the brain, which is associated with stress reduction. This second form of exposure to NO also inhibits the re-uptake of dopamine, which may contribute to dopaminergic receptor stimulation and thus to the acute rewarding effects of nicotine. The important role of NO in nicotine addiction is further supported by the finding that in animals NO synthase (NOS) inhibitors attenuate symptoms of the nicotine abstinence syndrome. NO may contribute to the development of cigarette smoking and nicotine addiction since: (1) inhaled NO from smoke may be able to increase nicotine absorption, (2) NO released through nicotine reduces symptoms of stress, (3) NO endogenously released by nicotine increases post-synaptic dopamine levels, and (4) NOS inhibitors attenuate symptoms of the nicotine abstinence syndrome. It remains to be determined whether reducing the NO content in cigarette smoke may reduce nicotine absorption. It also needs to be clarified whether NOS inhibitors or a low L-arginine diet might be useful in the treatment of nicotine addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215243     DOI: 10.1080/14622200210142724

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  14 in total

1.  Nitric Oxide Mediated Degradation of CYP2A6 via the Ubiquitin-Proteasome Pathway in Human Hepatoma Cells.

Authors:  John Cerrone; Choon-Myung Lee; Tian Mi; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2020-04-29       Impact factor: 3.922

2.  Acute effect of cigarette smoke and nicotine on airway blood flow and airflow in healthy smokers.

Authors:  Kanwaldeep Randhawa; Eliana Mendes; Adam Wanner
Journal:  Lung       Date:  2006-11-16       Impact factor: 2.584

3.  Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Stephanie S O'Malley
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

4.  Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: Electrophysiological and neurochemical evidence in rats.

Authors:  Vincenzo Di Matteo; Massimo Pierucci; Arcangelo Benigno; Ennio Esposito; Giuseppe Crescimanno; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2010-03-25       Impact factor: 5.243

5.  Upregulation of norepinephrine transporter function by prolonged exposure to nicotine in cultured bovine adrenal medullary cells.

Authors:  Hideaki Itoh; Yumiko Toyohira; Susumu Ueno; Satoru Saeki; Han Zhang; Yumi Furuno; Kojiro Takahashi; Masato Tsutsui; Kenji Hachisuka; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-31       Impact factor: 3.000

Review 6.  Cognitive enhancers in the treatment of substance use disorders: clinical evidence.

Authors:  Kathleen T Brady; Kevin M Gray; Bryan K Tolliver
Journal:  Pharmacol Biochem Behav       Date:  2011-04-29       Impact factor: 3.533

7.  Naphthoquinones and bioactive compounds from tobacco as modulators of neuronal nitric oxide synthase activity.

Authors:  Priya Venkatakrishnan; C Gary Gairola; Neal Castagnoli; R Timothy Miller
Journal:  Phytother Res       Date:  2009-12       Impact factor: 5.878

8.  Temporal structure/function variation in cultured differentiated human nasal epithelium associated with acute single exposure to tobacco smoke or E-cigarette vapor.

Authors:  Johnny L Carson; Laura Zhou; Luisa Brighton; Katherine H Mills; Haibo Zhou; Ilona Jaspers; Milan Hazucha
Journal:  Inhal Toxicol       Date:  2017-02       Impact factor: 2.724

9.  Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.

Authors:  Anja Rudolph; Roger L Milne; Thérèse Truong; Julia A Knight; Petra Seibold; Dieter Flesch-Janys; Sabine Behrens; Ursula Eilber; Manjeet K Bolla; Qin Wang; Joe Dennis; Alison M Dunning; Mitul Shah; Hannah R Munday; Hatef Darabi; Mikael Eriksson; Judith S Brand; Janet Olson; Celine M Vachon; Emily Hallberg; J Esteban Castelao; Angel Carracedo; Maria Torres; Jingmei Li; Keith Humphreys; Emilie Cordina-Duverger; Florence Menegaux; Henrik Flyger; Børge G Nordestgaard; Sune F Nielsen; Betul T Yesilyurt; Giuseppe Floris; Karin Leunen; Ellen G Engelhardt; Annegien Broeks; Emiel J Rutgers; Gord Glendon; Anna Marie Mulligan; Simon Cross; Malcolm Reed; Anna Gonzalez-Neira; José Ignacio Arias Perez; Elena Provenzano; Carmel Apicella; Melissa C Southey; Amanda Spurdle; Lothar Häberle; Matthias W Beckmann; Arif B Ekici; Aida Karina Dieffenbach; Volker Arndt; Christa Stegmaier; Catriona McLean; Laura Baglietto; Stephen J Chanock; Jolanta Lissowska; Mark E Sherman; Thomas Brüning; Ute Hamann; Yon-Dschun Ko; Nick Orr; Minouk Schoemaker; Alan Ashworth; Veli-Matti Kosma; Vesa Kataja; Jaana M Hartikainen; Arto Mannermaa; Anthony Swerdlow; Graham G Giles; Hermann Brenner; Peter A Fasching; Georgia Chenevix-Trench; John Hopper; Javier Benítez; Angela Cox; Irene L Andrulis; Diether Lambrechts; Manuela Gago-Dominguez; Fergus Couch; Kamila Czene; Stig E Bojesen; Doug F Easton; Marjanka K Schmidt; Pascal Guénel; Per Hall; Paul D P Pharoah; Montserrat Garcia-Closas; Jenny Chang-Claude
Journal:  Int J Cancer       Date:  2014-09-23       Impact factor: 7.396

Review 10.  Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review).

Authors:  Sergej Nadalin; Hrvoje Jakovac; Vjekoslav Peitl; Dalibor Karlović; Alena Buretić-Tomljanović
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.